Oncology has long been a major focus of R&D activities, and it is projected to be the area with the largest proportion of clinical development spending, with 37% of total pipeline expenditure and 28% of total pipeline FDA approvals, over the next 6 years.
Yet, there are many unmet needs for the patient undergoing cancer treatment. Developing improved therapies and providing patients with a choice in the way these therapies are administered are necessary for creating more effective and patient friendly treatments. We see R&D costs are rising and only half of all Phase III drugs reach the market. So how do pharmaceutical companies maximize the chance of their oncology drug being in the right half of that statistic?
This webinar will place the oncology patient and the drug company at the heart of the conversation and will give situational awareness of the challenges both parties face, along with the proven solutions to help overcome these challenges.